| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mental Disorders | 44 | 2023 | 6598 | 2.820 |
Why?
|
| Neurosciences | 14 | 2019 | 348 | 2.530 |
Why?
|
| Corpus Striatum | 22 | 2021 | 1221 | 1.740 |
Why?
|
| Enkephalins | 19 | 1999 | 154 | 1.700 |
Why?
|
| National Institute of Mental Health (U.S.) | 14 | 2018 | 107 | 1.540 |
Why?
|
| Brain Diseases | 5 | 2021 | 1563 | 1.380 |
Why?
|
| Schizophrenia | 19 | 2023 | 6882 | 1.320 |
Why?
|
| Protein Precursors | 19 | 1999 | 1154 | 1.270 |
Why?
|
| Cocaine | 17 | 2008 | 1007 | 1.250 |
Why?
|
| Dopamine | 16 | 2007 | 1591 | 1.170 |
Why?
|
| Multifactorial Inheritance | 5 | 2021 | 1195 | 1.110 |
Why?
|
| Drug Discovery | 4 | 2014 | 1058 | 1.050 |
Why?
|
| Morals | 2 | 2021 | 285 | 0.990 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 13 | 1999 | 514 | 0.910 |
Why?
|
| Cell Adhesion Molecules, Neuronal | 2 | 2015 | 266 | 0.900 |
Why?
|
| Brain | 46 | 2021 | 26388 | 0.850 |
Why?
|
| Autistic Disorder | 4 | 2021 | 1185 | 0.850 |
Why?
|
| Psychiatry | 10 | 2022 | 1695 | 0.810 |
Why?
|
| Anger | 2 | 2021 | 402 | 0.710 |
Why?
|
| Substance-Related Disorders | 18 | 2011 | 4257 | 0.690 |
Why?
|
| Nervous System Diseases | 4 | 2014 | 1622 | 0.680 |
Why?
|
| Gene Expression Regulation | 29 | 2008 | 12073 | 0.670 |
Why?
|
| Neurons | 23 | 2022 | 9340 | 0.670 |
Why?
|
| Biology | 2 | 2021 | 295 | 0.670 |
Why?
|
| Nerve Tissue Proteins | 11 | 2015 | 4463 | 0.660 |
Why?
|
| Genes, fos | 11 | 1998 | 183 | 0.620 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 5 | 2013 | 1953 | 0.610 |
Why?
|
| Human Genome Project | 3 | 2011 | 193 | 0.610 |
Why?
|
| Receptors, Metabotropic Glutamate | 2 | 2012 | 211 | 0.600 |
Why?
|
| DNA Copy Number Variations | 4 | 2023 | 1941 | 0.600 |
Why?
|
| Ethical Analysis | 1 | 2017 | 42 | 0.590 |
Why?
|
| Obsessive-Compulsive Disorder | 3 | 2021 | 1444 | 0.570 |
Why?
|
| Synaptic Transmission | 6 | 2015 | 1178 | 0.570 |
Why?
|
| Neurobiology | 3 | 2013 | 121 | 0.540 |
Why?
|
| Public-Private Sector Partnerships | 1 | 2016 | 121 | 0.530 |
Why?
|
| Research Support as Topic | 2 | 2016 | 705 | 0.530 |
Why?
|
| Animal Experimentation | 1 | 2015 | 45 | 0.520 |
Why?
|
| Research Personnel | 3 | 2015 | 573 | 0.510 |
Why?
|
| Neurotransmitter Agents | 7 | 2010 | 647 | 0.500 |
Why?
|
| Genetic Research | 1 | 2015 | 174 | 0.500 |
Why?
|
| Psychotropic Drugs | 7 | 2003 | 894 | 0.500 |
Why?
|
| Receptors, Neurotransmitter | 6 | 2005 | 178 | 0.490 |
Why?
|
| Neuronal Plasticity | 10 | 2022 | 1423 | 0.480 |
Why?
|
| Cocaine-Related Disorders | 5 | 2008 | 460 | 0.480 |
Why?
|
| Human Experimentation | 3 | 2018 | 127 | 0.470 |
Why?
|
| Reward | 5 | 2007 | 940 | 0.470 |
Why?
|
| Drug Industry | 3 | 2016 | 746 | 0.470 |
Why?
|
| Biomedical Research | 4 | 2020 | 3309 | 0.460 |
Why?
|
| Narcotics | 4 | 1997 | 343 | 0.460 |
Why?
|
| Animals | 95 | 2021 | 168768 | 0.450 |
Why?
|
| Proto-Oncogene Proteins c-fos | 7 | 1999 | 575 | 0.450 |
Why?
|
| Behavior | 4 | 2005 | 561 | 0.440 |
Why?
|
| Cyclic AMP | 10 | 1999 | 1472 | 0.430 |
Why?
|
| Glutamic Acid | 6 | 2003 | 1169 | 0.430 |
Why?
|
| Histone Deacetylase 2 | 1 | 2012 | 74 | 0.430 |
Why?
|
| Personal Autonomy | 2 | 2012 | 298 | 0.420 |
Why?
|
| Research | 7 | 2002 | 1999 | 0.410 |
Why?
|
| Synapses | 7 | 2022 | 1728 | 0.410 |
Why?
|
| Genetics, Medical | 1 | 2014 | 338 | 0.400 |
Why?
|
| Memory | 5 | 2006 | 2174 | 0.400 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 3 | 1999 | 494 | 0.400 |
Why?
|
| Humans | 144 | 2023 | 744366 | 0.400 |
Why?
|
| Gene Expression | 16 | 2002 | 7798 | 0.400 |
Why?
|
| Antipsychotic Agents | 3 | 2014 | 3057 | 0.390 |
Why?
|
| National Institutes of Health (U.S.) | 5 | 2019 | 780 | 0.390 |
Why?
|
| Lie Detection | 1 | 2010 | 9 | 0.390 |
Why?
|
| Phenotype | 9 | 2022 | 16367 | 0.380 |
Why?
|
| Terrorism | 2 | 2005 | 211 | 0.380 |
Why?
|
| Choice Behavior | 3 | 2012 | 802 | 0.370 |
Why?
|
| Genetic Predisposition to Disease | 9 | 2022 | 17446 | 0.370 |
Why?
|
| Guilt | 1 | 2010 | 95 | 0.360 |
Why?
|
| Central Nervous System Stimulants | 2 | 2012 | 1148 | 0.360 |
Why?
|
| Cyclins | 2 | 2003 | 603 | 0.360 |
Why?
|
| Nootropic Agents | 1 | 2011 | 160 | 0.350 |
Why?
|
| Rats | 32 | 2018 | 24252 | 0.340 |
Why?
|
| Alternative Splicing | 3 | 2006 | 1117 | 0.340 |
Why?
|
| Disease Models, Animal | 8 | 2021 | 18034 | 0.340 |
Why?
|
| Violence | 1 | 2015 | 909 | 0.330 |
Why?
|
| Hypothalamus | 4 | 1995 | 1063 | 0.330 |
Why?
|
| Enhancer Elements, Genetic | 8 | 1999 | 1340 | 0.320 |
Why?
|
| Depression | 5 | 2017 | 7759 | 0.320 |
Why?
|
| International Classification of Diseases | 2 | 2011 | 867 | 0.320 |
Why?
|
| Biotechnology | 1 | 2010 | 281 | 0.320 |
Why?
|
| Models, Neurological | 6 | 2014 | 1775 | 0.320 |
Why?
|
| Genes, Immediate-Early | 3 | 2001 | 101 | 0.310 |
Why?
|
| Grooming | 1 | 2007 | 37 | 0.310 |
Why?
|
| Stress, Physiological | 3 | 2006 | 1403 | 0.300 |
Why?
|
| Receptors, Dopamine D1 | 4 | 2005 | 291 | 0.300 |
Why?
|
| Volition | 1 | 2007 | 63 | 0.290 |
Why?
|
| Receptors, Dopamine | 4 | 1996 | 295 | 0.280 |
Why?
|
| Child Behavior | 1 | 2012 | 839 | 0.280 |
Why?
|
| Behavior, Addictive | 3 | 2007 | 462 | 0.280 |
Why?
|
| Brain-Derived Neurotrophic Factor | 2 | 2007 | 604 | 0.280 |
Why?
|
| Adaptation, Physiological | 2 | 2007 | 1312 | 0.280 |
Why?
|
| Depressive Disorder | 3 | 2017 | 3747 | 0.280 |
Why?
|
| Imipramine | 1 | 2006 | 97 | 0.280 |
Why?
|
| Second Messenger Systems | 3 | 1995 | 206 | 0.280 |
Why?
|
| Association Learning | 2 | 2006 | 224 | 0.270 |
Why?
|
| Social Behavior | 2 | 2015 | 1127 | 0.270 |
Why?
|
| Serotonin | 4 | 2007 | 1017 | 0.270 |
Why?
|
| Psychology, Clinical | 2 | 2019 | 42 | 0.260 |
Why?
|
| Schizophrenic Psychology | 3 | 2008 | 1678 | 0.260 |
Why?
|
| Models, Biological | 5 | 2018 | 9584 | 0.260 |
Why?
|
| Compulsive Behavior | 2 | 2007 | 117 | 0.260 |
Why?
|
| Amphetamines | 3 | 1998 | 148 | 0.260 |
Why?
|
| Superior Cervical Ganglion | 2 | 1994 | 33 | 0.250 |
Why?
|
| Amphetamine | 2 | 1996 | 225 | 0.240 |
Why?
|
| Neostriatum | 4 | 2007 | 250 | 0.240 |
Why?
|
| Embryo, Mammalian | 5 | 2021 | 1701 | 0.240 |
Why?
|
| Cognition | 5 | 2011 | 6770 | 0.240 |
Why?
|
| Transcription Factor AP-1 | 4 | 2003 | 317 | 0.240 |
Why?
|
| Rats, Sprague-Dawley | 15 | 2005 | 8300 | 0.240 |
Why?
|
| Dopamine Uptake Inhibitors | 2 | 2008 | 312 | 0.240 |
Why?
|
| Biological Psychiatry | 3 | 2017 | 25 | 0.240 |
Why?
|
| Phosphorylation | 16 | 2005 | 8436 | 0.240 |
Why?
|
| Social Responsibility | 1 | 2007 | 388 | 0.230 |
Why?
|
| Adolescent Behavior | 1 | 2012 | 1151 | 0.230 |
Why?
|
| Life Change Events | 1 | 2009 | 938 | 0.230 |
Why?
|
| Social Environment | 1 | 2009 | 1022 | 0.230 |
Why?
|
| Growth Inhibitors | 3 | 1994 | 385 | 0.230 |
Why?
|
| Goals | 2 | 2007 | 707 | 0.230 |
Why?
|
| Genomics | 3 | 2022 | 5717 | 0.230 |
Why?
|
| Ethics Committees | 2 | 2000 | 54 | 0.230 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2005 | 489 | 0.220 |
Why?
|
| Brain Chemistry | 3 | 2000 | 982 | 0.220 |
Why?
|
| beta-Galactosidase | 5 | 1996 | 574 | 0.220 |
Why?
|
| Health Services Needs and Demand | 2 | 2014 | 1410 | 0.220 |
Why?
|
| Data Collection | 2 | 2023 | 3339 | 0.220 |
Why?
|
| Crack Cocaine | 1 | 2001 | 32 | 0.210 |
Why?
|
| Genes | 3 | 2000 | 1893 | 0.200 |
Why?
|
| Lymphokines | 3 | 1994 | 949 | 0.200 |
Why?
|
| Bipolar Disorder | 4 | 2023 | 5027 | 0.200 |
Why?
|
| Mental Health Services | 4 | 2002 | 1644 | 0.200 |
Why?
|
| Substance Withdrawal Syndrome | 3 | 1996 | 632 | 0.200 |
Why?
|
| Genetics | 1 | 2002 | 112 | 0.200 |
Why?
|
| Cognition Disorders | 4 | 2011 | 4043 | 0.200 |
Why?
|
| Maternal Exposure | 1 | 2008 | 961 | 0.200 |
Why?
|
| Emotions | 5 | 2007 | 2659 | 0.200 |
Why?
|
| DNA-Binding Proteins | 10 | 2002 | 9647 | 0.190 |
Why?
|
| Psychopharmacology | 1 | 2003 | 143 | 0.190 |
Why?
|
| Transcription Factors | 10 | 2002 | 12207 | 0.190 |
Why?
|
| Cyclohexanecarboxylic Acids | 1 | 2001 | 141 | 0.190 |
Why?
|
| Occupational Health Services | 1 | 2002 | 154 | 0.190 |
Why?
|
| DiGeorge Syndrome | 1 | 2022 | 177 | 0.190 |
Why?
|
| Behavioral Sciences | 1 | 2000 | 31 | 0.190 |
Why?
|
| Mice, Transgenic | 10 | 2021 | 9735 | 0.190 |
Why?
|
| Cholinergic Agents | 1 | 2021 | 93 | 0.190 |
Why?
|
| Cooperative Behavior | 2 | 2020 | 1504 | 0.190 |
Why?
|
| Antidepressive Agents | 3 | 2014 | 2838 | 0.180 |
Why?
|
| United States | 25 | 2019 | 69872 | 0.180 |
Why?
|
| Calcium | 6 | 2005 | 5755 | 0.180 |
Why?
|
| Receptors, Serotonin | 2 | 1998 | 201 | 0.180 |
Why?
|
| Amines | 1 | 2001 | 276 | 0.180 |
Why?
|
| Serotonin Antagonists | 2 | 1998 | 144 | 0.180 |
Why?
|
| Signal Transduction | 12 | 2007 | 23404 | 0.180 |
Why?
|
| Fear | 2 | 1998 | 1440 | 0.180 |
Why?
|
| Methylphenidate | 1 | 2003 | 473 | 0.170 |
Why?
|
| Penetrance | 1 | 2021 | 381 | 0.170 |
Why?
|
| Nervous System Malformations | 1 | 2001 | 247 | 0.170 |
Why?
|
| Phosphoserine | 1 | 1999 | 206 | 0.170 |
Why?
|
| Preimplantation Diagnosis | 1 | 2021 | 151 | 0.170 |
Why?
|
| Promoter Regions, Genetic | 7 | 2006 | 5867 | 0.170 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 2 | 2012 | 3658 | 0.170 |
Why?
|
| RNA, Messenger | 16 | 2008 | 13035 | 0.160 |
Why?
|
| Cost of Illness | 4 | 2001 | 1860 | 0.160 |
Why?
|
| Databases as Topic | 1 | 2000 | 475 | 0.160 |
Why?
|
| Membrane Proteins | 2 | 2014 | 7882 | 0.160 |
Why?
|
| Base Sequence | 15 | 1996 | 12797 | 0.160 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 4 | 2007 | 896 | 0.160 |
Why?
|
| Immediate-Early Proteins | 2 | 1992 | 453 | 0.160 |
Why?
|
| Cells, Cultured | 14 | 2006 | 19233 | 0.160 |
Why?
|
| Molecular Sequence Data | 15 | 2001 | 18111 | 0.150 |
Why?
|
| Ethics, Research | 1 | 1999 | 191 | 0.150 |
Why?
|
| Genome-Wide Association Study | 6 | 2022 | 12262 | 0.150 |
Why?
|
| Genetics, Behavioral | 3 | 2004 | 53 | 0.150 |
Why?
|
| Genetic Testing | 3 | 2021 | 3444 | 0.150 |
Why?
|
| RNA Polymerase II | 1 | 2001 | 550 | 0.150 |
Why?
|
| Amygdala | 3 | 2004 | 1315 | 0.150 |
Why?
|
| History, 21st Century | 2 | 2018 | 1534 | 0.150 |
Why?
|
| Peer Review, Research | 1 | 2020 | 329 | 0.150 |
Why?
|
| Nucleus Accumbens | 2 | 1997 | 366 | 0.150 |
Why?
|
| Monosaccharide Transport Proteins | 5 | 1998 | 440 | 0.150 |
Why?
|
| Mice | 19 | 2021 | 81201 | 0.150 |
Why?
|
| History, 20th Century | 3 | 2018 | 2740 | 0.140 |
Why?
|
| Substance P | 2 | 1995 | 335 | 0.140 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2003 | 1284 | 0.140 |
Why?
|
| Denmark | 1 | 2019 | 738 | 0.140 |
Why?
|
| Genetic Variation | 4 | 2021 | 6542 | 0.140 |
Why?
|
| Learning | 2 | 2005 | 1711 | 0.140 |
Why?
|
| src-Family Kinases | 1 | 1999 | 551 | 0.140 |
Why?
|
| Nervous System | 2 | 2006 | 554 | 0.140 |
Why?
|
| Education | 1 | 1999 | 543 | 0.140 |
Why?
|
| Public Health | 2 | 2007 | 2602 | 0.140 |
Why?
|
| gamma-Aminobutyric Acid | 2 | 2001 | 1121 | 0.140 |
Why?
|
| Confidentiality | 1 | 2000 | 612 | 0.140 |
Why?
|
| Models, Genetic | 3 | 2014 | 3493 | 0.140 |
Why?
|
| Interneurons | 1 | 2021 | 577 | 0.140 |
Why?
|
| Placebos | 2 | 2000 | 1676 | 0.140 |
Why?
|
| Animal Rights | 1 | 2015 | 10 | 0.130 |
Why?
|
| Tissue Banks | 1 | 2016 | 184 | 0.130 |
Why?
|
| Blood-Brain Barrier | 6 | 1998 | 1019 | 0.130 |
Why?
|
| Mood Disorders | 2 | 2001 | 1106 | 0.130 |
Why?
|
| Health Priorities | 2 | 2014 | 380 | 0.130 |
Why?
|
| Twin Studies as Topic | 1 | 2015 | 105 | 0.130 |
Why?
|
| Workplace | 1 | 2002 | 836 | 0.130 |
Why?
|
| Genes, jun | 2 | 1992 | 71 | 0.130 |
Why?
|
| Tyrosine 3-Monooxygenase | 2 | 1994 | 375 | 0.130 |
Why?
|
| Cues | 3 | 2007 | 875 | 0.130 |
Why?
|
| Privacy | 2 | 2010 | 238 | 0.130 |
Why?
|
| Liver Regeneration | 1 | 2016 | 210 | 0.130 |
Why?
|
| Choline O-Acetyltransferase | 2 | 1995 | 150 | 0.130 |
Why?
|
| Borderline Personality Disorder | 1 | 2002 | 736 | 0.130 |
Why?
|
| Pan troglodytes | 1 | 2015 | 229 | 0.130 |
Why?
|
| Alcoholism | 2 | 1995 | 1906 | 0.130 |
Why?
|
| Health Policy | 2 | 2014 | 2661 | 0.120 |
Why?
|
| Brassica | 1 | 1994 | 38 | 0.120 |
Why?
|
| Aging | 5 | 2009 | 8664 | 0.120 |
Why?
|
| Recombinant Fusion Proteins | 2 | 1994 | 3773 | 0.120 |
Why?
|
| Chromatin | 1 | 2006 | 2933 | 0.120 |
Why?
|
| Central Nervous System Agents | 1 | 2014 | 72 | 0.120 |
Why?
|
| Biomedical Technology | 1 | 2016 | 220 | 0.120 |
Why?
|
| Neural Pathways | 2 | 2006 | 2974 | 0.120 |
Why?
|
| Haloperidol | 2 | 1993 | 397 | 0.120 |
Why?
|
| Neurosecretory Systems | 1 | 1995 | 231 | 0.120 |
Why?
|
| Observer Variation | 2 | 2010 | 2593 | 0.120 |
Why?
|
| Psychotic Disorders | 2 | 2023 | 3046 | 0.120 |
Why?
|
| Genetic Linkage | 3 | 2002 | 2421 | 0.120 |
Why?
|
| Vasoactive Intestinal Peptide | 5 | 1994 | 179 | 0.120 |
Why?
|
| Behavior, Animal | 3 | 2008 | 1881 | 0.120 |
Why?
|
| Stress, Psychological | 2 | 2007 | 4245 | 0.120 |
Why?
|
| Software | 2 | 2019 | 4441 | 0.120 |
Why?
|
| Clinical Trials as Topic | 5 | 2003 | 7914 | 0.110 |
Why?
|
| Genetic Engineering | 1 | 1999 | 951 | 0.110 |
Why?
|
| Ethics, Medical | 1 | 1999 | 792 | 0.110 |
Why?
|
| Inheritance Patterns | 1 | 2015 | 340 | 0.110 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 2 | 1998 | 491 | 0.110 |
Why?
|
| Fertilization in Vitro | 1 | 2021 | 1284 | 0.110 |
Why?
|
| Dopamine Agonists | 3 | 2005 | 355 | 0.110 |
Why?
|
| Alleles | 2 | 2022 | 6933 | 0.110 |
Why?
|
| Substantia Nigra | 1 | 1994 | 353 | 0.110 |
Why?
|
| Molecular Targeted Therapy | 2 | 2014 | 2725 | 0.110 |
Why?
|
| Consciousness | 1 | 2018 | 572 | 0.110 |
Why?
|
| Genitalia, Male | 1 | 1992 | 84 | 0.110 |
Why?
|
| Drug Repositioning | 1 | 2014 | 230 | 0.110 |
Why?
|
| Models, Psychological | 2 | 2008 | 811 | 0.110 |
Why?
|
| Anxiety | 3 | 2007 | 4293 | 0.110 |
Why?
|
| Genes, Synthetic | 1 | 1992 | 90 | 0.110 |
Why?
|
| Peptic Ulcer | 1 | 1994 | 223 | 0.110 |
Why?
|
| Diagnostic Imaging | 2 | 2004 | 3508 | 0.100 |
Why?
|
| PC12 Cells | 2 | 2003 | 331 | 0.100 |
Why?
|
| Clozapine | 2 | 1993 | 498 | 0.100 |
Why?
|
| Organoids | 1 | 2018 | 701 | 0.100 |
Why?
|
| Proto-Oncogenes | 1 | 1993 | 321 | 0.100 |
Why?
|
| Psychophysiologic Disorders | 1 | 1994 | 228 | 0.100 |
Why?
|
| Guidelines as Topic | 1 | 2018 | 1405 | 0.100 |
Why?
|
| Dextroamphetamine | 1 | 1992 | 129 | 0.100 |
Why?
|
| Forecasting | 5 | 2002 | 2951 | 0.100 |
Why?
|
| Paraventricular Hypothalamic Nucleus | 3 | 1999 | 113 | 0.100 |
Why?
|
| Cognitive Science | 2 | 2002 | 14 | 0.100 |
Why?
|
| Genitalia, Female | 1 | 1992 | 146 | 0.100 |
Why?
|
| Transfection | 6 | 2005 | 5895 | 0.100 |
Why?
|
| Neuropeptides | 2 | 1994 | 942 | 0.100 |
Why?
|
| Prenatal Exposure Delayed Effects | 2 | 2001 | 2408 | 0.100 |
Why?
|
| Mutation | 2 | 2015 | 29786 | 0.100 |
Why?
|
| Chromosome Mapping | 5 | 2008 | 4740 | 0.100 |
Why?
|
| 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine | 2 | 2005 | 54 | 0.100 |
Why?
|
| Excitatory Amino Acid Antagonists | 2 | 2005 | 449 | 0.100 |
Why?
|
| Information Storage and Retrieval | 1 | 2016 | 824 | 0.100 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2022 | 1736 | 0.090 |
Why?
|
| Cerebrospinal Fluid | 3 | 1989 | 535 | 0.090 |
Why?
|
| Activating Transcription Factor 1 | 2 | 2002 | 26 | 0.090 |
Why?
|
| GTP-Binding Proteins | 1 | 1995 | 970 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-jun | 3 | 1999 | 286 | 0.090 |
Why?
|
| Helicobacter pylori | 1 | 1994 | 383 | 0.090 |
Why?
|
| Helicobacter Infections | 1 | 1994 | 387 | 0.090 |
Why?
|
| Interleukin-6 | 3 | 1994 | 3203 | 0.090 |
Why?
|
| Dopamine Antagonists | 2 | 2005 | 296 | 0.090 |
Why?
|
| Rett Syndrome | 2 | 2006 | 165 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 8 | 2010 | 35425 | 0.090 |
Why?
|
| In Situ Hybridization | 4 | 1995 | 1950 | 0.090 |
Why?
|
| Animals, Newborn | 5 | 2008 | 2726 | 0.090 |
Why?
|
| Drug Interactions | 3 | 2005 | 1460 | 0.090 |
Why?
|
| Informed Consent | 4 | 2018 | 995 | 0.090 |
Why?
|
| Genome, Human | 3 | 2017 | 4420 | 0.090 |
Why?
|
| Psychotherapy | 3 | 2007 | 1642 | 0.090 |
Why?
|
| Ciliary Neurotrophic Factor | 5 | 1996 | 77 | 0.090 |
Why?
|
| ras Proteins | 1 | 1994 | 1060 | 0.080 |
Why?
|
| Phorbol Esters | 1 | 1989 | 111 | 0.080 |
Why?
|
| Environmental Exposure | 1 | 2023 | 4232 | 0.080 |
Why?
|
| DNA | 6 | 2003 | 7294 | 0.080 |
Why?
|
| Treatment Failure | 1 | 2014 | 2618 | 0.080 |
Why?
|
| Replication Protein C | 1 | 2008 | 19 | 0.080 |
Why?
|
| Benzazepines | 2 | 2005 | 326 | 0.080 |
Why?
|
| World Health Organization | 2 | 2011 | 1318 | 0.080 |
Why?
|
| Stress Disorders, Post-Traumatic | 2 | 2005 | 4266 | 0.080 |
Why?
|
| Binding Sites | 5 | 2006 | 6111 | 0.080 |
Why?
|
| Information Dissemination | 1 | 2016 | 1099 | 0.080 |
Why?
|
| False Positive Reactions | 1 | 2010 | 980 | 0.080 |
Why?
|
| Central Nervous System | 1 | 1995 | 1357 | 0.080 |
Why?
|
| Motivation | 2 | 2014 | 1971 | 0.080 |
Why?
|
| Enzyme Inhibitors | 3 | 2005 | 3799 | 0.080 |
Why?
|
| Sequence Analysis, RNA | 1 | 2015 | 2012 | 0.080 |
Why?
|
| Cross-Cultural Comparison | 1 | 2011 | 651 | 0.070 |
Why?
|
| International Cooperation | 1 | 2014 | 1420 | 0.070 |
Why?
|
| Drive | 1 | 2007 | 35 | 0.070 |
Why?
|
| Brain Mapping | 3 | 2004 | 6670 | 0.070 |
Why?
|
| Supraoptic Nucleus | 3 | 1999 | 28 | 0.070 |
Why?
|
| Maryland | 1 | 2007 | 276 | 0.070 |
Why?
|
| Stochastic Processes | 1 | 2008 | 344 | 0.070 |
Why?
|
| Disease Progression | 1 | 2023 | 13286 | 0.070 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2022 | 15520 | 0.070 |
Why?
|
| Risk Factors | 7 | 2015 | 72296 | 0.070 |
Why?
|
| Nerve Growth Factors | 3 | 1994 | 574 | 0.070 |
Why?
|
| Leukemia Inhibitory Factor | 3 | 1994 | 61 | 0.070 |
Why?
|
| Maternal Behavior | 1 | 2009 | 311 | 0.070 |
Why?
|
| Activating Transcription Factor 2 | 2 | 1997 | 45 | 0.070 |
Why?
|
| Environment | 2 | 2003 | 1123 | 0.070 |
Why?
|
| Reproducibility of Results | 4 | 2010 | 19905 | 0.070 |
Why?
|
| Calcium-Transporting ATPases | 1 | 2006 | 123 | 0.070 |
Why?
|
| Awareness | 1 | 2010 | 640 | 0.070 |
Why?
|
| Receptors, Dopamine D2 | 3 | 1994 | 475 | 0.070 |
Why?
|
| Neuropsychology | 1 | 2007 | 110 | 0.070 |
Why?
|
| Proteomics | 1 | 2019 | 3638 | 0.070 |
Why?
|
| Protein Kinase C | 2 | 2005 | 1227 | 0.070 |
Why?
|
| Transcription, Genetic | 7 | 1997 | 7721 | 0.070 |
Why?
|
| Bone and Bones | 1 | 2016 | 2576 | 0.070 |
Why?
|
| Hospitals, Psychiatric | 1 | 2007 | 332 | 0.070 |
Why?
|
| Ventral Tegmental Area | 1 | 2007 | 142 | 0.070 |
Why?
|
| Prefrontal Cortex | 2 | 2007 | 2147 | 0.070 |
Why?
|
| Methoxyhydroxyphenylglycol | 1 | 2005 | 93 | 0.070 |
Why?
|
| Phenylacetates | 1 | 2005 | 114 | 0.060 |
Why?
|
| Dynorphins | 1 | 2005 | 84 | 0.060 |
Why?
|
| Dicarboxylic Acids | 1 | 2005 | 69 | 0.060 |
Why?
|
| Internal-External Control | 1 | 2007 | 363 | 0.060 |
Why?
|
| Oligonucleotide Probes | 2 | 1996 | 427 | 0.060 |
Why?
|
| Fragile X Syndrome | 1 | 2006 | 115 | 0.060 |
Why?
|
| Excitatory Amino Acid Agonists | 1 | 2005 | 146 | 0.060 |
Why?
|
| Cholera Toxin | 1 | 1987 | 556 | 0.060 |
Why?
|
| Massachusetts | 1 | 2018 | 8662 | 0.060 |
Why?
|
| Disabled Persons | 1 | 2014 | 1212 | 0.060 |
Why?
|
| Judgment | 1 | 2007 | 281 | 0.060 |
Why?
|
| Comorbidity | 1 | 2019 | 10388 | 0.060 |
Why?
|
| Drug Prescriptions | 1 | 2014 | 1637 | 0.060 |
Why?
|
| Sequence Analysis, DNA | 1 | 2015 | 4805 | 0.060 |
Why?
|
| Recurrence | 2 | 2007 | 8340 | 0.060 |
Why?
|
| Pharmaceutical Preparations | 1 | 2012 | 1070 | 0.060 |
Why?
|
| Glutamates | 1 | 2005 | 398 | 0.060 |
Why?
|
| Drug Tolerance | 2 | 1996 | 376 | 0.060 |
Why?
|
| Calcium Channel Blockers | 1 | 1987 | 692 | 0.060 |
Why?
|
| Costs and Cost Analysis | 1 | 2010 | 1680 | 0.060 |
Why?
|
| Benzoates | 1 | 2005 | 217 | 0.060 |
Why?
|
| Facial Expression | 2 | 1998 | 508 | 0.060 |
Why?
|
| Saline Solution, Hypertonic | 2 | 1994 | 110 | 0.060 |
Why?
|
| DNA Mutational Analysis | 4 | 2002 | 4185 | 0.060 |
Why?
|
| Consensus Development Conferences, NIH as Topic | 1 | 2003 | 28 | 0.060 |
Why?
|
| Cloning, Molecular | 3 | 1996 | 4320 | 0.060 |
Why?
|
| Potassium Chloride | 1 | 2003 | 237 | 0.060 |
Why?
|
| Kinetics | 6 | 1999 | 6476 | 0.060 |
Why?
|
| Carrier Proteins | 3 | 2006 | 5023 | 0.050 |
Why?
|
| Limbic System | 2 | 1996 | 426 | 0.050 |
Why?
|
| Blotting, Western | 2 | 2005 | 5181 | 0.050 |
Why?
|
| Child | 5 | 2021 | 77709 | 0.050 |
Why?
|
| RNA | 3 | 2022 | 2749 | 0.050 |
Why?
|
| Rats, Inbred Strains | 4 | 1992 | 2186 | 0.050 |
Why?
|
| Pregnancy | 6 | 2005 | 29144 | 0.050 |
Why?
|
| Biomedical Enhancement | 1 | 2002 | 8 | 0.050 |
Why?
|
| Choroid Plexus | 2 | 1998 | 231 | 0.050 |
Why?
|
| Lithium | 2 | 1996 | 601 | 0.050 |
Why?
|
| Neuropharmacology | 1 | 2002 | 21 | 0.050 |
Why?
|
| Male | 29 | 2012 | 350115 | 0.050 |
Why?
|
| Time | 1 | 2003 | 542 | 0.050 |
Why?
|
| Finland | 1 | 2023 | 602 | 0.050 |
Why?
|
| Response Elements | 1 | 2003 | 312 | 0.050 |
Why?
|
| Glycine | 1 | 2005 | 671 | 0.050 |
Why?
|
| Cost-Benefit Analysis | 1 | 2014 | 5388 | 0.050 |
Why?
|
| Career Mobility | 2 | 2020 | 262 | 0.050 |
Why?
|
| Adoption | 1 | 2002 | 97 | 0.050 |
Why?
|
| Somatostatin | 3 | 1994 | 459 | 0.050 |
Why?
|
| Opioid-Related Disorders | 1 | 1996 | 2064 | 0.050 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2014 | 2104 | 0.050 |
Why?
|
| Oligodeoxyribonucleotides | 2 | 1993 | 708 | 0.050 |
Why?
|
| Early Growth Response Protein 1 | 2 | 1992 | 138 | 0.050 |
Why?
|
| Arginine Vasopressin | 2 | 1991 | 130 | 0.050 |
Why?
|
| History, 19th Century | 1 | 2003 | 720 | 0.050 |
Why?
|
| Macromolecular Substances | 1 | 2003 | 1454 | 0.050 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2005 | 2505 | 0.050 |
Why?
|
| Patient Advocacy | 2 | 1999 | 353 | 0.050 |
Why?
|
| United States Dept. of Health and Human Services | 1 | 2000 | 90 | 0.050 |
Why?
|
| Substance Abuse Treatment Centers | 1 | 2001 | 168 | 0.050 |
Why?
|
| Acetates | 1 | 2001 | 311 | 0.050 |
Why?
|
| Research Design | 3 | 2022 | 5984 | 0.050 |
Why?
|
| Personnel Selection | 1 | 2002 | 190 | 0.050 |
Why?
|
| Twins | 1 | 2002 | 339 | 0.050 |
Why?
|
| Cerebral Cortex | 3 | 2003 | 5709 | 0.040 |
Why?
|
| Mind-Body Relations, Metaphysical | 1 | 2000 | 38 | 0.040 |
Why?
|
| Purines | 1 | 2003 | 594 | 0.040 |
Why?
|
| Polymorphism, Genetic | 2 | 2000 | 4328 | 0.040 |
Why?
|
| Psychophysiology | 1 | 2000 | 135 | 0.040 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 3 | 1994 | 794 | 0.040 |
Why?
|
| Quinones | 1 | 1999 | 76 | 0.040 |
Why?
|
| Rifabutin | 1 | 1999 | 52 | 0.040 |
Why?
|
| COS Cells | 1 | 2001 | 1161 | 0.040 |
Why?
|
| Phenylethanolamine N-Methyltransferase | 2 | 1990 | 18 | 0.040 |
Why?
|
| Immunohistochemistry | 8 | 1998 | 11366 | 0.040 |
Why?
|
| Synaptic Potentials | 1 | 2019 | 43 | 0.040 |
Why?
|
| Fetus | 2 | 1998 | 1880 | 0.040 |
Why?
|
| Egtazic Acid | 1 | 1999 | 173 | 0.040 |
Why?
|
| Synaptosomes | 1 | 2019 | 115 | 0.040 |
Why?
|
| Disaster Planning | 1 | 2005 | 549 | 0.040 |
Why?
|
| Salicylamides | 2 | 1998 | 33 | 0.040 |
Why?
|
| Rabbits | 8 | 1999 | 4894 | 0.040 |
Why?
|
| Psychopathology | 1 | 2022 | 409 | 0.040 |
Why?
|
| Nomifensine | 1 | 1998 | 15 | 0.040 |
Why?
|
| Knowledge Bases | 1 | 2019 | 85 | 0.040 |
Why?
|
| Ritanserin | 1 | 1998 | 9 | 0.040 |
Why?
|
| Ethics, Clinical | 1 | 1999 | 101 | 0.040 |
Why?
|
| Tissue Distribution | 5 | 1996 | 2327 | 0.040 |
Why?
|
| Mentally Ill Persons | 1 | 1999 | 126 | 0.040 |
Why?
|
| Tropanes | 1 | 1998 | 51 | 0.040 |
Why?
|
| Financing, Organized | 1 | 2020 | 202 | 0.040 |
Why?
|
| Benzoquinones | 1 | 1999 | 201 | 0.040 |
Why?
|
| Receptors, Serotonin, 5-HT3 | 1 | 1998 | 43 | 0.040 |
Why?
|
| N-Methylaspartate | 1 | 1999 | 231 | 0.040 |
Why?
|
| Oxidopamine | 2 | 1998 | 169 | 0.040 |
Why?
|
| Alzheimer Disease | 2 | 2014 | 8038 | 0.040 |
Why?
|
| Glucose Transporter Type 1 | 5 | 1998 | 193 | 0.040 |
Why?
|
| Receptors, Glutamate | 2 | 1996 | 232 | 0.040 |
Why?
|
| Oncostatin M | 2 | 1994 | 28 | 0.040 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2014 | 3712 | 0.040 |
Why?
|
| Phosphoproteins | 2 | 1998 | 2441 | 0.040 |
Why?
|
| Iodine | 1 | 2000 | 286 | 0.040 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2001 | 671 | 0.040 |
Why?
|
| Omentum | 1 | 1999 | 170 | 0.040 |
Why?
|
| Endothelium, Vascular | 5 | 1998 | 4459 | 0.040 |
Why?
|
| Capillaries | 3 | 1998 | 773 | 0.040 |
Why?
|
| Female | 21 | 2012 | 380193 | 0.040 |
Why?
|
| Mental Competency | 1 | 1999 | 176 | 0.040 |
Why?
|
| Cell Proliferation | 2 | 2016 | 10483 | 0.040 |
Why?
|
| Cerebrospinal Fluid Shunts | 1 | 1999 | 189 | 0.040 |
Why?
|
| Symporters | 1 | 2000 | 361 | 0.040 |
Why?
|
| Bioethics | 1 | 2019 | 116 | 0.040 |
Why?
|
| Lactams, Macrocyclic | 1 | 1999 | 320 | 0.040 |
Why?
|
| Drug Therapy | 1 | 2000 | 497 | 0.040 |
Why?
|
| Leucine Zippers | 1 | 1997 | 117 | 0.040 |
Why?
|
| Chromosome Aberrations | 2 | 2002 | 1813 | 0.040 |
Why?
|
| Administrative Personnel | 1 | 1998 | 187 | 0.040 |
Why?
|
| Mental Health | 1 | 2011 | 3010 | 0.040 |
Why?
|
| Hematoporphyrins | 2 | 1988 | 23 | 0.040 |
Why?
|
| Social Support | 1 | 2007 | 2118 | 0.040 |
Why?
|
| Organizational Policy | 1 | 1999 | 429 | 0.040 |
Why?
|
| Tegmentum Mesencephali | 1 | 1996 | 59 | 0.040 |
Why?
|
| Chimera | 1 | 2018 | 485 | 0.040 |
Why?
|
| Hippocampus | 2 | 2006 | 3675 | 0.030 |
Why?
|
| National Health Programs | 1 | 2000 | 445 | 0.030 |
Why?
|
| Arteriosclerosis | 2 | 1993 | 1092 | 0.030 |
Why?
|
| 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone | 1 | 1995 | 7 | 0.030 |
Why?
|
| Dizocilpine Maleate | 1 | 1996 | 176 | 0.030 |
Why?
|
| Cell Membrane | 1 | 2006 | 3749 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2005 | 6366 | 0.030 |
Why?
|
| Adenosine-5'-(N-ethylcarboxamide) | 1 | 1995 | 15 | 0.030 |
Why?
|
| Budgets | 1 | 1998 | 229 | 0.030 |
Why?
|
| Chlordiazepoxide | 1 | 1995 | 42 | 0.030 |
Why?
|
| Autoradiography | 2 | 1995 | 745 | 0.030 |
Why?
|
| Habituation, Psychophysiologic | 1 | 1996 | 154 | 0.030 |
Why?
|
| Health Care Rationing | 1 | 1999 | 437 | 0.030 |
Why?
|
| Career Choice | 1 | 2002 | 744 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2009 | 3646 | 0.030 |
Why?
|
| Amino Acid Sequence | 2 | 2001 | 13814 | 0.030 |
Why?
|
| Proto-Oncogene Proteins | 3 | 1996 | 4554 | 0.030 |
Why?
|
| Ownership | 1 | 2018 | 332 | 0.030 |
Why?
|
| Receptors, Opioid, mu | 1 | 1996 | 182 | 0.030 |
Why?
|
| Conditioning, Classical | 1 | 1998 | 366 | 0.030 |
Why?
|
| Locus Coeruleus | 1 | 1996 | 176 | 0.030 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 1997 | 452 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2010 | 14723 | 0.030 |
Why?
|
| RNA Probes | 1 | 1995 | 113 | 0.030 |
Why?
|
| Interleukin-1 | 1 | 1999 | 1263 | 0.030 |
Why?
|
| Indole Alkaloids | 1 | 1994 | 24 | 0.030 |
Why?
|
| Sodium Chloride | 1 | 1997 | 625 | 0.030 |
Why?
|
| Quinpirole | 1 | 1994 | 33 | 0.030 |
Why?
|
| 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine | 1 | 1994 | 57 | 0.030 |
Why?
|
| Ergolines | 1 | 1994 | 61 | 0.030 |
Why?
|
| Diazepam | 1 | 1995 | 205 | 0.030 |
Why?
|
| Genetics, Population | 1 | 2019 | 934 | 0.030 |
Why?
|
| Basal Ganglia | 1 | 1997 | 546 | 0.030 |
Why?
|
| Finite Element Analysis | 1 | 2016 | 431 | 0.030 |
Why?
|
| Cell Line | 2 | 2022 | 16000 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2010 | 12961 | 0.030 |
Why?
|
| Adolescent | 5 | 2011 | 85779 | 0.030 |
Why?
|
| Narcotic Antagonists | 2 | 1999 | 562 | 0.030 |
Why?
|
| Ondansetron | 1 | 1994 | 90 | 0.030 |
Why?
|
| Morphine | 2 | 1996 | 657 | 0.030 |
Why?
|
| Predictive Value of Tests | 2 | 2021 | 15078 | 0.030 |
Why?
|
| Levodopa | 1 | 1994 | 219 | 0.030 |
Why?
|
| Injections, Intraventricular | 2 | 1999 | 231 | 0.030 |
Why?
|
| Histocytochemistry | 1 | 1995 | 719 | 0.030 |
Why?
|
| Epithelial Cells | 1 | 2006 | 3690 | 0.030 |
Why?
|
| Osmotic Pressure | 1 | 1994 | 151 | 0.030 |
Why?
|
| Staurosporine | 1 | 1994 | 251 | 0.030 |
Why?
|
| Thyroid Gland | 1 | 2000 | 1173 | 0.030 |
Why?
|
| Patient Care | 1 | 1999 | 640 | 0.030 |
Why?
|
| Hematoporphyrin Photoradiation | 1 | 1993 | 17 | 0.030 |
Why?
|
| Alkaloids | 1 | 1994 | 190 | 0.030 |
Why?
|
| Substance Abuse, Intravenous | 1 | 1998 | 525 | 0.030 |
Why?
|
| Attitude of Health Personnel | 1 | 2007 | 3841 | 0.030 |
Why?
|
| Educational Status | 1 | 2021 | 2540 | 0.030 |
Why?
|
| Death | 1 | 2018 | 678 | 0.030 |
Why?
|
| Psychiatric Status Rating Scales | 2 | 2002 | 6036 | 0.030 |
Why?
|
| Enzyme Activation | 1 | 1999 | 3702 | 0.030 |
Why?
|
| Peptides | 3 | 1994 | 4410 | 0.030 |
Why?
|
| Carbazoles | 1 | 1994 | 226 | 0.030 |
Why?
|
| Isoquinolines | 1 | 1994 | 366 | 0.030 |
Why?
|
| Mice, Knockout | 2 | 1999 | 14561 | 0.030 |
Why?
|
| Amino Acid Isomerases | 1 | 1992 | 34 | 0.030 |
Why?
|
| Receptors, Dopamine D4 | 1 | 1993 | 171 | 0.030 |
Why?
|
| Psychometrics | 1 | 2002 | 3003 | 0.030 |
Why?
|
| Suicide, Attempted | 1 | 2001 | 1218 | 0.030 |
Why?
|
| Hydrocephalus | 1 | 1999 | 748 | 0.030 |
Why?
|
| Blood Volume | 1 | 1994 | 565 | 0.030 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 1997 | 1213 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 1998 | 1461 | 0.030 |
Why?
|
| Naloxone | 1 | 1994 | 367 | 0.030 |
Why?
|
| Oligonucleotides, Antisense | 1 | 1994 | 433 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2008 | 10943 | 0.030 |
Why?
|
| Neuroblastoma | 3 | 1994 | 1226 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 3 | 1994 | 6313 | 0.030 |
Why?
|
| Peptidylprolyl Isomerase | 1 | 1992 | 105 | 0.030 |
Why?
|
| Databases, Genetic | 1 | 2019 | 1783 | 0.030 |
Why?
|
| Astrocytes | 1 | 1999 | 1273 | 0.030 |
Why?
|
| Time Factors | 6 | 2008 | 40075 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 1999 | 4933 | 0.020 |
Why?
|
| Lipopolysaccharides | 1 | 1999 | 2216 | 0.020 |
Why?
|
| Antimanic Agents | 1 | 1995 | 522 | 0.020 |
Why?
|
| Nuclear Proteins | 3 | 1993 | 5856 | 0.020 |
Why?
|
| Adaptation, Psychological | 1 | 2002 | 2575 | 0.020 |
Why?
|
| Up-Regulation | 2 | 1999 | 4222 | 0.020 |
Why?
|
| Family | 1 | 2002 | 3147 | 0.020 |
Why?
|
| Oligonucleotides | 1 | 1994 | 572 | 0.020 |
Why?
|
| Calcimycin | 1 | 1990 | 222 | 0.020 |
Why?
|
| Chromaffin System | 1 | 1990 | 16 | 0.020 |
Why?
|
| Adenosine | 1 | 1995 | 825 | 0.020 |
Why?
|
| Blotting, Northern | 1 | 1992 | 1581 | 0.020 |
Why?
|
| Cold Temperature | 1 | 1994 | 772 | 0.020 |
Why?
|
| Protein Binding | 2 | 2006 | 9384 | 0.020 |
Why?
|
| Pineal Gland | 1 | 1991 | 166 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2014 | 11726 | 0.020 |
Why?
|
| Indoles | 1 | 1998 | 1839 | 0.020 |
Why?
|
| Zinc Fingers | 1 | 1992 | 583 | 0.020 |
Why?
|
| Calmodulin | 1 | 1990 | 209 | 0.020 |
Why?
|
| DNA, Complementary | 1 | 1993 | 2050 | 0.020 |
Why?
|
| Temporal Lobe | 1 | 1997 | 1670 | 0.020 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1998 | 2232 | 0.020 |
Why?
|
| Plasmids | 1 | 1995 | 2308 | 0.020 |
Why?
|
| Benzodiazepines | 1 | 1995 | 1101 | 0.020 |
Why?
|
| Catheterization, Peripheral | 1 | 1993 | 345 | 0.020 |
Why?
|
| Adult | 11 | 2004 | 214052 | 0.020 |
Why?
|
| Species Specificity | 2 | 1998 | 2478 | 0.020 |
Why?
|
| HIV Infections | 1 | 1995 | 16715 | 0.020 |
Why?
|
| Drug Synergism | 2 | 1990 | 1794 | 0.020 |
Why?
|
| Oximes | 1 | 1990 | 311 | 0.020 |
Why?
|
| Health Care Reform | 1 | 1998 | 1261 | 0.020 |
Why?
|
| Deoxyribonuclease I | 1 | 1989 | 229 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2000 | 9849 | 0.020 |
Why?
|
| Swine | 1 | 2018 | 5918 | 0.020 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 2008 | 135 | 0.020 |
Why?
|
| Age Factors | 3 | 2008 | 18373 | 0.020 |
Why?
|
| Cell Lineage | 1 | 2016 | 2504 | 0.020 |
Why?
|
| Parkinson Disease | 1 | 2001 | 2775 | 0.020 |
Why?
|
| Microscopy, Electron | 3 | 1998 | 2646 | 0.020 |
Why?
|
| Cerebrospinal Fluid Proteins | 1 | 1987 | 69 | 0.020 |
Why?
|
| Ferricyanides | 1 | 1987 | 32 | 0.020 |
Why?
|
| Hypotension, Controlled | 1 | 1987 | 15 | 0.020 |
Why?
|
| Organ Specificity | 1 | 1992 | 2008 | 0.020 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 1996 | 2455 | 0.020 |
Why?
|
| Electrophysiology | 1 | 1990 | 1308 | 0.020 |
Why?
|
| Binding, Competitive | 1 | 1988 | 1157 | 0.020 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 1991 | 703 | 0.020 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 1988 | 769 | 0.020 |
Why?
|
| Nitroprusside | 1 | 1987 | 275 | 0.020 |
Why?
|
| Trans-Activators | 1 | 1996 | 2926 | 0.020 |
Why?
|
| Physicians | 2 | 2002 | 4567 | 0.020 |
Why?
|
| Exploratory Behavior | 1 | 2008 | 270 | 0.020 |
Why?
|
| Cerebral Ventricles | 1 | 1989 | 544 | 0.020 |
Why?
|
| Glucose | 2 | 1998 | 4398 | 0.020 |
Why?
|
| Attitude to Health | 1 | 1995 | 2052 | 0.020 |
Why?
|
| Cats | 1 | 1987 | 1000 | 0.020 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1987 | 1375 | 0.020 |
Why?
|
| Orbit | 1 | 1989 | 426 | 0.020 |
Why?
|
| Cerebrovascular Circulation | 4 | 1998 | 2732 | 0.020 |
Why?
|
| Genotype | 1 | 2000 | 12952 | 0.020 |
Why?
|
| Locomotion | 1 | 2008 | 378 | 0.020 |
Why?
|
| Dextrans | 1 | 1987 | 595 | 0.020 |
Why?
|
| Encephalitis | 1 | 1989 | 425 | 0.020 |
Why?
|
| Phototherapy | 1 | 1988 | 377 | 0.020 |
Why?
|
| Seizures | 1 | 1998 | 2859 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2008 | 767 | 0.020 |
Why?
|
| Editorial Policies | 1 | 2009 | 451 | 0.020 |
Why?
|
| Animals, Suckling | 2 | 1994 | 72 | 0.020 |
Why?
|
| Models, Theoretical | 1 | 2016 | 3589 | 0.020 |
Why?
|
| Serum Albumin | 1 | 1987 | 675 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 1993 | 2969 | 0.020 |
Why?
|
| Depressive Disorder, Major | 1 | 2002 | 4639 | 0.010 |
Why?
|
| Piperazines | 1 | 1994 | 2488 | 0.010 |
Why?
|
| Prevalence | 1 | 2000 | 15221 | 0.010 |
Why?
|
| Drainage | 1 | 1989 | 1142 | 0.010 |
Why?
|
| Ion Channels | 1 | 1988 | 1056 | 0.010 |
Why?
|
| Mannitol | 3 | 1991 | 181 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 1998 | 13991 | 0.010 |
Why?
|
| Publishing | 1 | 2009 | 833 | 0.010 |
Why?
|
| Gastric Stump | 1 | 1961 | 8 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2019 | 21748 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2019 | 7282 | 0.010 |
Why?
|
| Duodenal Ulcer | 1 | 1961 | 125 | 0.010 |
Why?
|
| Dihematoporphyrin Ether | 2 | 1993 | 31 | 0.010 |
Why?
|
| Dogs | 1 | 2006 | 3912 | 0.010 |
Why?
|
| Ascites | 1 | 1963 | 344 | 0.010 |
Why?
|
| Neuropsychological Tests | 1 | 2013 | 6994 | 0.010 |
Why?
|
| Glucocorticoids | 1 | 1990 | 2108 | 0.010 |
Why?
|
| Action Potentials | 1 | 1988 | 1806 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 1992 | 4561 | 0.010 |
Why?
|
| Biological Transport | 2 | 1998 | 2120 | 0.010 |
Why?
|
| Treatment Outcome | 2 | 1999 | 63107 | 0.010 |
Why?
|
| Serum Albumin, Radio-Iodinated | 1 | 1999 | 37 | 0.010 |
Why?
|
| Chromium Radioisotopes | 1 | 1999 | 36 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2009 | 5077 | 0.010 |
Why?
|
| Cytokines | 1 | 1994 | 7323 | 0.010 |
Why?
|
| Sugar Acids | 1 | 1999 | 24 | 0.010 |
Why?
|
| Guinea Pigs | 2 | 1991 | 1386 | 0.010 |
Why?
|
| Societies | 1 | 1999 | 104 | 0.010 |
Why?
|
| Drug Administration Routes | 1 | 1999 | 153 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 2 | 1998 | 21833 | 0.010 |
Why?
|
| Organotechnetium Compounds | 1 | 1999 | 137 | 0.010 |
Why?
|
| Financial Support | 1 | 1999 | 115 | 0.010 |
Why?
|
| Dopamine and cAMP-Regulated Phosphoprotein 32 | 1 | 1998 | 31 | 0.010 |
Why?
|
| Edetic Acid | 1 | 1999 | 275 | 0.010 |
Why?
|
| Financing, Government | 1 | 2002 | 468 | 0.010 |
Why?
|
| Raclopride | 1 | 1998 | 97 | 0.010 |
Why?
|
| Stimulation, Chemical | 1 | 1998 | 326 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 1999 | 25039 | 0.010 |
Why?
|
| Child, Preschool | 2 | 1998 | 41005 | 0.010 |
Why?
|
| Protein Kinase Inhibitors | 1 | 1994 | 5534 | 0.010 |
Why?
|
| Dopamine Agents | 1 | 1998 | 189 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2018 | 23336 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 2 | 1998 | 6171 | 0.010 |
Why?
|
| Cell Polarity | 1 | 2000 | 645 | 0.010 |
Why?
|
| Mentors | 1 | 2002 | 631 | 0.010 |
Why?
|
| Tissue Fixation | 1 | 1998 | 241 | 0.010 |
Why?
|
| Thyrotropin | 1 | 2000 | 849 | 0.010 |
Why?
|
| Gastrectomy | 1 | 1961 | 663 | 0.010 |
Why?
|
| Papio | 1 | 1998 | 656 | 0.010 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 1998 | 338 | 0.010 |
Why?
|
| Perfusion | 2 | 1991 | 1360 | 0.010 |
Why?
|
| Medical Records | 1 | 1961 | 1413 | 0.010 |
Why?
|
| Sodium-Potassium-Exchanging ATPase | 1 | 1998 | 494 | 0.010 |
Why?
|
| STAT1 Transcription Factor | 1 | 1996 | 320 | 0.010 |
Why?
|
| Anesthesia | 1 | 1987 | 1561 | 0.010 |
Why?
|
| Radioisotope Dilution Technique | 1 | 1994 | 70 | 0.010 |
Why?
|
| Iodine Radioisotopes | 1 | 1999 | 1032 | 0.010 |
Why?
|
| Happiness | 1 | 1996 | 170 | 0.010 |
Why?
|
| Gene Targeting | 1 | 1998 | 880 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 21 | 1 | 1995 | 230 | 0.010 |
Why?
|
| Regional Blood Flow | 1 | 1998 | 1525 | 0.010 |
Why?
|
| Microscopy, Immunoelectron | 1 | 1994 | 319 | 0.010 |
Why?
|
| Radionuclide Imaging | 1 | 1999 | 2031 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 22 | 1 | 1995 | 351 | 0.010 |
Why?
|
| Janus Kinase 2 | 1 | 1996 | 528 | 0.010 |
Why?
|
| Radiography | 1 | 2004 | 7023 | 0.010 |
Why?
|
| Weaning | 1 | 1993 | 105 | 0.010 |
Why?
|
| Carbon Radioisotopes | 1 | 1994 | 577 | 0.010 |
Why?
|
| Diet, Atherogenic | 1 | 1993 | 95 | 0.010 |
Why?
|
| Codeine | 1 | 1972 | 49 | 0.010 |
Why?
|
| Cell Culture Techniques | 1 | 2000 | 1678 | 0.010 |
Why?
|
| Subcellular Fractions | 1 | 1993 | 547 | 0.010 |
Why?
|
| STAT3 Transcription Factor | 1 | 1996 | 874 | 0.010 |
Why?
|
| Heart Rate | 2 | 1998 | 4092 | 0.010 |
Why?
|
| Erythrocyte Membrane | 1 | 1994 | 442 | 0.010 |
Why?
|
| Heroin | 1 | 1972 | 117 | 0.010 |
Why?
|
| Visual Pathways | 1 | 1996 | 565 | 0.010 |
Why?
|
| Chromosome Disorders | 1 | 1995 | 514 | 0.010 |
Why?
|
| Stomach Neoplasms | 1 | 1961 | 1332 | 0.010 |
Why?
|
| X Chromosome | 1 | 1995 | 814 | 0.010 |
Why?
|
| Fiber Optic Technology | 1 | 1993 | 290 | 0.010 |
Why?
|
| Clomipramine | 1 | 1990 | 54 | 0.010 |
Why?
|
| Deamino Arginine Vasopressin | 1 | 1991 | 91 | 0.010 |
Why?
|
| 1-Naphthylamine | 1 | 1990 | 49 | 0.010 |
Why?
|
| Fluvoxamine | 1 | 1990 | 74 | 0.010 |
Why?
|
| Laparoscopy | 1 | 1963 | 2150 | 0.010 |
Why?
|
| Tunica Intima | 1 | 1993 | 464 | 0.010 |
Why?
|
| Calcitonin Gene-Related Peptide | 1 | 1993 | 306 | 0.010 |
Why?
|
| Methadone | 1 | 1972 | 306 | 0.010 |
Why?
|
| Education, Medical | 1 | 2002 | 1722 | 0.010 |
Why?
|
| Injections, Intravenous | 2 | 1988 | 1420 | 0.010 |
Why?
|
| Visual Cortex | 1 | 1998 | 1149 | 0.010 |
Why?
|
| Aorta, Abdominal | 1 | 1993 | 646 | 0.010 |
Why?
|
| DNA, Mitochondrial | 1 | 1995 | 817 | 0.010 |
Why?
|
| Aged | 2 | 2001 | 163288 | 0.010 |
Why?
|
| Mathematics | 1 | 1991 | 728 | 0.010 |
Why?
|
| Subarachnoid Space | 1 | 1989 | 79 | 0.010 |
Why?
|
| Sertraline | 1 | 1990 | 206 | 0.010 |
Why?
|
| Tritium | 2 | 1984 | 745 | 0.010 |
Why?
|
| Radiopharmaceuticals | 1 | 1999 | 2645 | 0.010 |
Why?
|
| Glioma | 1 | 1984 | 3401 | 0.010 |
Why?
|
| Sheep | 1 | 1991 | 1437 | 0.000 |
Why?
|
| Blood Pressure | 2 | 1998 | 8551 | 0.000 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 1988 | 821 | 0.000 |
Why?
|
| Gene Deletion | 1 | 1994 | 2751 | 0.000 |
Why?
|
| Oxygen | 1 | 1998 | 4189 | 0.000 |
Why?
|
| Fluoxetine | 1 | 1990 | 749 | 0.000 |
Why?
|
| Developmental Disabilities | 1 | 1995 | 1456 | 0.000 |
Why?
|
| Cell Differentiation | 2 | 1994 | 11486 | 0.000 |
Why?
|
| Receptors, Adrenergic, beta | 1 | 1987 | 246 | 0.000 |
Why?
|
| Catecholamines | 1 | 1987 | 387 | 0.000 |
Why?
|
| Optic Nerve | 1 | 1989 | 554 | 0.000 |
Why?
|
| Meta-Analysis as Topic | 1 | 1990 | 1342 | 0.000 |
Why?
|
| Adrenal Glands | 1 | 1987 | 546 | 0.000 |
Why?
|
| Escherichia coli Infections | 1 | 1989 | 532 | 0.000 |
Why?
|
| Hematoporphyrin Derivative | 1 | 1984 | 10 | 0.000 |
Why?
|
| Drug Stability | 1 | 1984 | 291 | 0.000 |
Why?
|
| Muscles | 1 | 1988 | 1614 | 0.000 |
Why?
|
| Rats, Inbred F344 | 1 | 1984 | 862 | 0.000 |
Why?
|
| Brain Neoplasms | 1 | 1984 | 8861 | 0.000 |
Why?
|
| Cattle | 1 | 1987 | 3922 | 0.000 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 1984 | 358 | 0.000 |
Why?
|
| Lipids | 1 | 1993 | 3307 | 0.000 |
Why?
|
| Aorta | 1 | 1988 | 2062 | 0.000 |
Why?
|
| Middle Aged | 3 | 2004 | 213390 | 0.000 |
Why?
|
| Ambulatory Care | 1 | 1990 | 2708 | 0.000 |
Why?
|
| Acute Disease | 1 | 1989 | 7147 | 0.000 |
Why?
|
| Peptide Fragments | 1 | 1991 | 5096 | 0.000 |
Why?
|
| Epilepsy | 1 | 1994 | 3310 | 0.000 |
Why?
|
| Double-Blind Method | 1 | 1990 | 12025 | 0.000 |
Why?
|
| Cohort Studies | 1 | 1996 | 40559 | 0.000 |
Why?
|
| Neoplasms | 1 | 1961 | 21696 | 0.000 |
Why?
|
| Carbon Isotopes | 1 | 1972 | 467 | 0.000 |
Why?
|
| Carotid Arteries | 1 | 1972 | 950 | 0.000 |
Why?
|